Kentaro Yamazaki

Shizuoka Cancer Center — Japan

Medicine · Health Sciences

46h-index14.4kcitations551works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(362), Gastric Cancer Management and Outcomes(159), Cancer Treatment and Pharmacology(136), Lung Cancer Treatments and Mutations(103), Genetic factors in colorectal cancer(88)

Publications550 total

Lecithinized superoxide dismutase prevents oxaliplatin-induced peripheral neuropathy: a double-blind, placebo-controlled, randomized phase II study
ESMO Gastrointestinal Oncology·2025Open Access
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial
Journal of Clinical Oncology·2025· 10 citedOpen Access
825P Chronological changes in clinical outcomes of standard first-line oxaliplatin-based chemotherapy + targeted agents for metastatic colorectal cancer: Updated analysis of the ARCAD database
Annals of Oncology·2025
Optimal number of needle passes in endoscopic ultrasound–guided tissue sampling for genomic profiling: a randomized, noncomparative trial
Gastrointestinal Endoscopy·2025· 1 cited
338P Interim report of the real-world data analysis of pemigatinib therapy for unresectable or recurrent biliary tract cancer patients in Japan with FGFR2 fusion or FGFR2 rearrangement (JON2303 B)
Annals of Oncology·2025Open Access
Multimodal treatments for patients with locally advanced synchronous esophageal and head and neck cancer
International Journal of Clinical Oncology·2025
Supplementary Figure S4 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Table 3 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Supplementary Figure S6 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Supplementary Figure S9 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Table 1 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Supplementary Figure S11 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Supplementary Figure S5 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Supplementary Table S3 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Supplementary Table S1 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Figure 3 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Data from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Supplementary Figure S10 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Supplementary Figure S2 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
Supplementary Table S4 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
2025Open Access
page 1 of 28Next →

Frequent Co-authors

Takayuki Yoshino(33), Kei Muro(18), Eiji Oki(13), Atsushi Ohtsu(12), Akihito Tsuji(11), Yoshito Komatsu(11), Takeshi Kato(11), Tomohiro Nishina(11), Takeharu Yamanaka(10), Kensei Yamaguchi(9), Hirofumi Yasui(9), Hideaki Bando(8), Katsuya Tsuchihara(8), Kohei Shitara(8), Narikazu Boku(7), Hiroya Taniguchi(7), Taito Esaki(7), Hiroyuki Uetake(6), Eric Van Cutsem(6), Yoshiaki Nakamura(6)